membranous nephropathy
Conditions
Interventions
Experimental group:Conventional therapy+sacubitril/valsartan 100mg bid
Control group:Conventional therapy+valsartan 160mg qd
Sponsors
China-Japan Friendship Hospital
Eligibility
Sex/Gender
All
Age
30 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. The pathological diagnosis of renal biopsy is membranous nephropathy, and secondary membranous nephropathy such as hepatitis B virus-related nephritis, lupus nephritis, tumor-related membranous nephropathy, drug- or poison-related membranous nephropathy is excluded; 2. The patient's 24-hour urine protein quantification is 0.5g-4g/d, and serum ALB>30g/L; 3. eGFR >=75ml/(min*1.73m^2); 4. Aged 30-75 years; 5. Have not received glucocorticoids or immunosuppressants, or biological agents such as rituximab before; 6. Voluntarily join the study and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Combined with renal artery stenosis; 2. Pregnant or breastfeeding patients; 3. Angioedema has occurred after taking RAS inhibitors; 4. History of malignant tumor or chronic infectious disease; 5. Abnormal liver function: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) exceeds 2 times the upper limit of normal; 6. ACS or cerebral infarction occurred within 3 months; 7. Severe cognitive impairment or dementia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 24 hours urine protein; | — |
Secondary
| Measure | Time frame |
|---|---|
| serum creatinine;serum albumin;estimated glomerular filtration rate;plasma atrial diuretic peptide;24-hour urinary cyclic guanosine monophosphate;blood pressure; | — |
Countries
China
Contacts
Public ContactLi Wen'ge
China-Japan Friendship Hospital
Outcome results
None listed